Готові списки джерел за темами / RHG

Добірка наукової літератури з теми "RHG"

Автор: Grafiati
Опубліковано: 14 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "RHG".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "RHG"

1

Senthilan, Pingkalai R., and Charlotte Helfrich-Förster. "Rhodopsin 7–The unusual Rhodopsin inDrosophila." PeerJ 4 (September 6, 2016): e2427. http://dx.doi.org/10.7717/peerj.2427.

Повний текст джерела
Анотація:
Rhodopsins are the major photopigments in the fruit flyDrosophila melanogaster. Drosophilaexpress six well-characterized Rhodopsins (Rh1–Rh6) with distinct absorption maxima and expression pattern. In 2000, when theDrosophilagenome was published, a novelRhodopsingene was discovered:Rhodopsin 7(Rh7).Rh7is highly conserved among theDrosophilagenus and is also found in other arthropods. Phylogenetic trees based on protein sequences suggest that the sevenDrosophilaRhodopsins cluster in three different groups. While Rh1, Rh2 and Rh6 form a “vertebrate-melanopsin-type”–cluster, and Rh3, Rh4 and Rh5 form an “insect-type”-Rhodopsin cluster, Rh7 seem to form its own cluster. Although Rh7 has nearly all important features of a functional Rhodopsin, it differs from other Rhodopsins in its genomic and structural properties, suggesting it might have an overall different role than other known Rhodopsins.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Holloway, T., C. Voigt, J. Morton, S. N. Spak, A. P. Rutter, and J. J. Schauer. "An assessment of atmospheric mercury in the Community Multiscale Air Quality (CMAQ) model." Atmospheric Chemistry and Physics Discussions 12, no. 1 (January 23, 2012): 2131–66. http://dx.doi.org/10.5194/acpd-12-2131-2012.

Повний текст джерела
Анотація:
Abstract. Quantitative analysis of three atmospheric mercury species – gaseous elemental mercury (Hg0), reactive gaseous mercury (RGHg) and particulate mercury (PHg) – has been limited to date by lack of ambient measurement data as well as by uncertainties in numerical models and emission inventories. This study employs the Community Multiscale Air Quality Model version 4.6 with mercury chemistry (CMAQ-Hg), to examine how local emissions, meteorology, atmospheric chemistry, and deposition affect mercury concentration and deposition the Great Lakes Region (GLR), and two sites in Wisconsin in particular: the rural Devil's Lake site and the urban Milwaukee site. Ambient mercury exhibits significant biases at both sites. Hg0 is too low in CMAQ-Hg, with the model showing a 6% low bias at the rural site and 36% low bias at the urban site. Reactive mercury (RHg = RGHg + PHg) is over-predicted by the model, with annual average biases >250%. Performance metrics for RHg are much worse than for mercury wet deposition, ozone (O3), nitrogen dioxide (NO2), or sulfur dioxide (SO2). Sensitivity simulations to isolate background inflow from regional emissions suggests that oxidation of imported Hg0 dominates model estimates of RHg at the rural study site (91% of base case value), and contributes 55% to the RHg at the urban site (local emissions contribute 45%). Limited evidence on the lifetime of RHg transported to the rural site suggests that modeled dry deposition rates are too high, possibly compensating for the erroneously high RHg values.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Holloway, T., C. Voigt, J. Morton, S. N. Spak, A. P. Rutter, and J. J. Schauer. "An assessment of atmospheric mercury in the Community Multiscale Air Quality (CMAQ) model at an urban site and a rural site in the Great Lakes Region of North America." Atmospheric Chemistry and Physics 12, no. 15 (August 7, 2012): 7117–33. http://dx.doi.org/10.5194/acp-12-7117-2012.

Повний текст джерела
Анотація:
Abstract. Quantitative analysis of three atmospheric mercury species – gaseous elemental mercury (Hg0), reactive gaseous mercury (RGHg) and particulate mercury (PHg) – has been limited to date by lack of ambient measurement data as well as by uncertainties in numerical models and emission inventories. This study employs the Community Multiscale Air Quality Model version 4.6 with mercury chemistry (CMAQ-Hg), to examine how local emissions, meteorology, atmospheric chemistry, and deposition affect mercury concentration and deposition the Great Lakes Region (GLR), and two sites in Wisconsin in particular: the rural Devil's Lake site and the urban Milwaukee site. Ambient mercury exhibits significant biases at both sites. Hg0 is too low in CMAQ-Hg, with the model showing a 6% low bias at the rural site and 36% low bias at the urban site. Reactive mercury (RHg = RGHg + PHg) is over-predicted by the model, with annual average biases >250%. Performance metrics for RHg are much worse than for mercury wet deposition, ozone (O3), nitrogen dioxide (NO2), or sulfur dioxide (SO2). Sensitivity simulations to isolate background inflow from regional emissions suggests that oxidation of imported Hg0 dominates model estimates of RHg at the rural study site (91% of base case value), and contributes 55% to the RHg at the urban site (local emissions contribute 45%).
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Sambo, Paolo, Franco Sannazzaro, and Michael R. Evans. "Physical Properties of Ground Fresh Rice Hulls and Sphagnum Peat Used for Greenhouse Root Substrates." HortTechnology 18, no. 3 (January 2008): 384–88. http://dx.doi.org/10.21273/horttech.18.3.384.

Повний текст джерела
Анотація:
Ground fresh rice (Oryza sativa) hull materials were produced by grinding whole fresh rice hulls and passing the resulting product through a 1-, 2-, 4- or 6-mm-diameter screen to produce a total of four ground rice products (RH1, RH2, RH4, and RH6, respectively). The physical properties and water release characteristics of sphagnum peatmoss (peat) and the four ground rice hull products were evaluated. All of the ground rice hull products had a higher bulk density (Bd) than peat, and as the grind size of the rice hull particle decreased, Bd increased. Peat had a higher total pore space (TPS) than all of the ground rice hull products except for RH6. As grind size decreased, the TPS decreased. Peat had a lower air-filled pore space (AFP) than all of the ground rice hull products and as the grind size of the rice hull products decreased, AFP decreased. Peat had a higher water holding capacity (WHC) than all of the ground rice hull products. Grind sizes RH4 and RH6 had similar WHC, whereas RH1 and RH2 had a higher WHC than RH4 and RH6. Peat, RH4, and RH6 had similar available water content (AVW), whereas RH2 had higher AVW than these materials and RH1 had the highest AVW. However, peat had the lowest AVW and easily available water (EAW) as a percentage of the WHC. The ground rice hull products RH1 and RH2 had the highest AVW and EAW of the components tested. Peat had the highest water content at container capacity. As pressure was increased from 1 to 5 kPa, peat released water more slowly than any of the ground rice hull products. The RH1 and RH2 ground hull products released water at a significantly higher rate than peat, but RH4 and RH6 released the most water over these pressures. For all rice hull products, most water was released between 1 and 2 kPa pressure. The rice hull products RH1 and RH2 had physical properties that were within recommended ranges and were most similar to those of peat.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Fan, Zhisong, Yu Su, Long Wang, Yudong Wang, Jing Zuo, Fengling Liu, and Da Jiang. "Bone pain associated with rhG-CSF or PEG-rhG-CSF in oncology patients." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19186-e19186. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19186.

Повний текст джерела
Анотація:
e19186 Background: Recombinant human granulocyte colonystimulating factor (rhG-CSF) and glycoPEGylated G-CSF (PEG-rhG-CSF) are two kinds of drugs in reducing the incidence and duration of neutropenia in oncology patients treated with chemotherapy. Although the acting time is different, bone pain is one of the most common adverse events in rhG-CSF and PEG-rhG-CSF. The purpose of this study is to describe the occurrence and management of bone pain in oncology patients receiving rhG-CSF and PEG-rhG-CSF. Methods: Two hundred and forty patients with malignant tumor received rhG-CSF or PEG-rhG-CSF after chemotherapy were enrolled to finish questionnaires about the side effect of bone pain. The incidence, location, duration, degree and treatment of bone pain after rhG-CSF or PEG-rhG-CSF used were collected and analyzed. Results: A total of 240 patients enrolled and 56.3% (135) patients had bone pain after rhG-CSF or PEG-rhG-CSF delivered. The most common parts of bone pain were thigh (35.6%), back (29.6%), waist (25.9%), shoulder (23.7%) and chest (21.5%). The bone pain of 39.2% patients last for 72h and 27.2% patients last less than 72h. The duration time of bone pain was longer in PEG-rhG-CSF than rhG-CSF. There was no significant difference in the rate of pain occurrence and the proportion of severe pain between rhG-CSF and PEG-rhG-CSF. Only 22.2% patients took drugs to relieve bone pain. Downregulated the doses of rhG-CSF or PEG-rhG-CSF could significantly relieve bone pain. Besides bone pain, 34.0% patients suffered muscle ache which was the second most side effect and occurred more often than runny nose and fever. Conclusions: The percentage of bone pain occurrence are similar in rhG-CSF and PEG-rhG-CSF, but the duration time was longer in PEG-rhG-CSF. For most patients, bone pain need not to deal with, Dose reductions can effectively relieve the mild to severe pain.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Yang, Wenyu, Tianfeng Liu, Xiaojuan Chen, Ye Guo, Ting Li, Benquan Qi, Fang Liu, et al. "A single-center, open-label clinical study to evaluate pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte stimulating factor in pediatric patients with acute lymphoblastic leukemia." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e22501-e22501. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22501.

Повний текст джерела
Анотація:
e22501 Background: The aims of the study were to investigate the pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF) in pediatric patients with acute lymphoblastic leukemia(ALL), and compare the efficacy and safety of PEG-rhG-CSF (brand name:jinyouli) and rhG-CSF. Methods: Pediatric patients with newly diagnosed ALL who planned to use CAM (cyclophosphamide, cytarabine, 6-mercaptopurine) for chemotherapy were assigned to PEG-rhG-CSF group or rhG-CSF group. In the PEG-rhG-CSF group, PEG-rhG-CSF (100ug/kg) was injected subcutaneously once 48 hours after chemotherapy. In the rhG-CSF group, rhG-CSF (150ug/d) was injected subcutaneously daily from 48 hours after chemotherapy until the absolute neutrophil count (ANC) was≥1.0×109/L. The serum concentration of PEG-rhG-CSF was detected by enzyme-linked immunosorbent assay (ELISA). Safety and efficacy of the two groups were evaluated. Results: Between November 2015 to April 2016, 17 pediatric patients were assigned to PEG-rhG-CSF(n = 9) or rhG-CSF(n = 8) groups. The main pharmacokinetic parameters (mean±SD) of PEG-rhG-CSF group were as follows: Cmax was 353.50±136.3 ng/ml, Tmax was 44.00±20.8 h, t1/2 was 14.58± 2.2h. The PEG-rhG-CSF serum concentration and ANC curve were consistent with the mechanism of neutrophil mediated clearance. The average value of ANC nadir in PEG-rhG-CSF group was 0.18 (±0.32)×109/L, and the rhG-CSF group was 0.08 (±0.09)×109/L, there was no significant difference between the two groups ( P = 0.469). Compared with rhG-CSF, the average time of ANC recovery in PEG-rhG-CSF group was earlier (18.33±2.18 vs. 21.50±2.33, P = 0.021). There were no significant differences in the incidence of FN and infection, the duration of grade Ⅳ neutropenia and hospitalization, and the safety of the two groups. Conclusions: PEG-rhG-CSF had favorable efficacy in pediatric patients with ALL receiving chemotherapy, and there was no serious adverse event. Compared with rhG-CSF, PEG-rhG-CSF needed only once in each chemotherapy cycle, which is more suitable for pediatric patients. Clinical trial information: NCT02953730.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Takatani, H., H. Soda, M. Fukuda, M. Watanabe, A. Kinoshita, T. Nakamura, and M. Oka. "Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts." Antimicrobial Agents and Chemotherapy 40, no. 4 (April 1996): 988–91. http://dx.doi.org/10.1128/aac.40.4.988.

Повний текст джерела
Анотація:
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is effective in countering chemotherapy-induced neutropenia. However, serum rhG-CSF levels cannot be maintained throughout the course of rhG-CSF therapy. The drop in serum rhG-CSF levels may vary with the duration of rhG-CSF administration or with the circulating neutrophil counts. We investigated the relationship between serum G-CSF levels and circulating neutrophil counts and the pharmacokinetics of rhG-CSF for patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF (lenograstim, 2 micrograms per kg of body weight per day). Twelve patients were randomly assigned to four groups with different rhG-CSF therapy schedules. Serum G-CSF levels were measured by an enzyme immunoassay method. Serum G-CSF levels during the rhG-CSF therapy greatly exceeded endogenous G-CSF levels and were mainly due to the presence of exogenous rhG-CSF rather than increased levels of endogenous G-CSF. Despite the duration of rhG-CSF administration, serum G-CSF levels during rhG-CSF therapy were inversely correlated with circulating neutrophil counts (r2 = 0.73, P < 0.0001). The value for the area under the concentration-time curve of rhG-CSF on the day of neutrophilia was lower than that on the day of neutropenia (P < 0.05). Our results suggest that the fall in serum G-CSF levels during rhG-CSF therapy may result from increased clearance and/or decreased absorption of rhG-CSF, two processes related to circulating neutrophil counts.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Pratiwi, Riyona Desvy, Dian Fitria Agustiyanti, Tri Isyani Tungga Dewi, Nina Herlina, Kartika Sari Dewi, Yuliawati Yuliawati, Aminah Aminah, and Asrul Muhamad Fuad. "Bioassay of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) for Neutropenia Treatment in Male Sprague Dawley Rats." Molecular and Cellular Biomedical Sciences 4, no. 1 (March 1, 2020): 10. http://dx.doi.org/10.21705/mcbs.v4i1.81.

Повний текст джерела
Анотація:
Background: Recombinant human granulocyte colony stimulating factor (rhG-CSF) is a first line therapy for neutropenia. However, it is less affordable for most patients in developing and poor countries. Therefore, biosimilar products are developed to suppress the cost of treatment, namely with rhG-CSF. This study aimed to explore the establishment of an affordable rhG-CSF that has similar potential to induce neutrophils recovery as the positive control.Materials and Methods: The rhG-CSF was expressed as inclusion body in Escherichia coli NiCo21(DE3). The inclusion body was then solubilized, refolded, purified and characterized prior to be used in the bioactivity assay. Cyclophosphamide-induced male Sprague Dawley rats were used as animal model and administered with rhG-CSF. Blood sample was collected at several points of time, before and after rhG-CSF treatments. Complete blood count and peripheral blood smear were conducted to investigate the activity of the rhG-CSF on each blood cells type, particularly neutrophil.Results: Specific activity on neutrophil proliferation was shown after treatments with our rhG-CSF and positive control. Positive control dose 40 mg/kg BW was statistically similar with that of the rhG-CSF dose 80 and 120 mg/kg BW. However, in neutropenic condition, recovery of neutrophil counts could not be achieved within 4 days of treatments. Thus, a longer treatment is needed to observe the activity of the rhG-CSF as an antineutropenia agent.Conclusion: The rhG-CSF has been proven having specific activity on neutrophil proliferation. However, improvement in the rhG-CSF preparation is still needed and longer administration of the rhG-CSF has to be applied in the future study.Keywords: rhG-CSF, biosimilar, neutropenia, Sprague Dawley rats
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Andrews, RG, RA Briddell, GH Knitter, T. Opie, M. Bronsden, D. Myerson, FR Appelbaum, and IK McNiece. "In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells." Blood 84, no. 3 (August 1, 1994): 800–810. http://dx.doi.org/10.1182/blood.v84.3.800.bloodjournal843800.

Повний текст джерела
Анотація:
Recombinant human stem cell factor (rhSCF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) are synergistic in vitro in stimulating the proliferation of hematopoietic progenitor cells and their precursors. We examined the in vivo synergy of rhSCF with rhG-CSF for stimulating hematopoiesis in vivo in baboons. Administration of low-dose (LD) rhSCF (25 micrograms/kg) alone did not stimulate changes in circulating WBCs. In comparison, administration of LD rhSCF in combination with rhG-CSF at 10 micrograms/kg or 100 micrograms/kg stimulated increases in circulating WBCs of multiple types up to twofold higher than was stimulated by administration of the same dose of rhG-CSF alone. When the dose of rhG-CSF is increased to 250 micrograms/kg, the administration of LD rhSCF does not further increase the circulating WBC counts. Administration of LD rhSCF in combination with rhG-CSF also stimulated increased circulation of hematopoietic progenitors. LD rhSCF alone stimulated less of an increase in circulating progenitors, per milliliter of blood, than did administration of rhG-CSF alone at 100 micrograms/kg. Baboons administered LD rhSCF together with rhG-CSF at 10, 100, or 250 micrograms/kg had 3.5- to 16-fold higher numbers per milliliter of blood of progenitors cells of multiple types, including colony-forming units granulocyte/macrophage (CFU-GM), burst-forming unit-erythroid (BFU-E), and colony-forming and burst-forming units-megakaryocyte (CFU- MK and BFU-MK) compared with animals given the same dose of rhG-CSF without rhSCF, regardless of the rhG-CSF dose. The increased circulation of progenitor cells stimulated by the combination of rhSCF plus rhG-CSF was not necessarily directly related to the increase in WBCs, as this effect on peripheral blood progenitors was observed even at an rhG-CSF dose of 250 micrograms/kg, where coadministration of LD rhSCF did not further increase WBC counts. Administration of very-low- dose rhSCF (2.5 micrograms/kg) with rhG-CSF, 10 micrograms/kg, did not stimulate increases in circulating WBCs, but did increase the number of megakaryocyte progenitor cells in blood compared with rhG-CSF alone. LD rhSCF administered alone for 7 days before rhG-CSF did not result in increased levels of circulating WBCs or progenitors compared with rhG- CSF alone. Thus, the synergistic effects of rhSCF with rhG-CSF were both dose- and time-dependent. The doses of rhSCF used in these studies have been tolerated in vivo in humans.(ABSTRACT TRUNCATED AT 400 WORDS).
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Ohsaka, A., S. Kitagawa, S. Sakamoto, Y. Miura, N. Takanashi, F. Takaku, and M. Saito. "In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma." Blood 74, no. 8 (December 1, 1989): 2743–48. http://dx.doi.org/10.1182/blood.v74.8.2743.2743.

Повний текст джерела
Анотація:
Abstract Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered (50 to 800 micrograms/m2) once daily as a half-hour intravenous (IV) infusion for 14 days to seven patients with malignant lymphoma. In all patients, administration of rhG-CSF not only ameliorated the decrease in absolute neutrophil count after the cytotoxic chemotherapy but also enhanced superoxide (O2-) release in neutrophils stimulated by N-formyl-methionyl-leucyl-phenylalanine (FMLP). The priming effect of rhG-CSF on neutrophil O2- release was rapid (evident within 6.5 hours) and sustained at least for 24 hours after a single IV administration of rhG-CSF. The responsiveness to further in vitro challenge of rhG-CSF was lost or reduced in neutrophils isolated after rhG-CSF treatment, indicating that neutrophils already primed in vivo by rhG-CSF are desensitized to this factor. In contrast to the results obtained with FMLP, when phorbol myristate acetate (PMA) was used as stimulus, no consistent enhancement of O2- release was observed, suggesting that rhG-CSF modulates the signal transduction pathways linked to FMLP receptors rather than increases the components of the O2- producing enzyme complexes. Administration of rhG-CSF also rapidly (evident within 15 minutes) caused an increase in expression of neutrophil C3bi-receptors that was sustained for at least 24 hours after a single IV administration of rhG- CSF. Pharmacokinetic study of rhG-CSF showed a half-life (t1/2) of 114 min. These findings show that rhG-CSF is a potent activator for neutrophil functions both in vivo and in vitro.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "RHG"

1

Lundin, Marika. "Verifiering av adsorption och elueringsmetod för identifiering av RhG-antikroppar." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-96825.

Повний текст джерела
Анотація:
Syftet med examensarbetet var att verifiera adsorptions- och elueringsmetod för detektion av G-antikroppar. Detta för att transfusionsmedicin i Karlskrona själva ska kunna genomföra utredning av G-antikroppar. En RhD-negativ gravid kvinna som bär på ett RhD-positivt barn är i behov av RhD-profylax. Har kvinnan redan bildat antikroppar mot RhD finns inte behovet av RhD-profylax. En RhD-negativ gravid kvinna som inte får RhD-profylax kan bilda antikroppar mot fostrets RhD-positiva erytrocyter vilket kan få allvarliga konsekvenser så som hemolytisk sjukdom hos foster och nyfödda. Då RhD-profylax är en dyr bristvara tas blodprover på mamman för att kontrollera fostrets RhD och kontrollera eventuellt behov av RhD-profylax. Det kontrolleras även om kvinnan har bildat några D-antikroppar. Problem som kan uppstå är att G-antikroppar serologisk liknar D och C-antikroppar, skulle då inte Gantikropparna upptäckas utan det anses vara D-antikroppar kommer den gravida kvinnan att gå miste om RhD-profylax hon är i behov av. Att urskilja D och Cantikroppar från att vara G-antikroppar genomförs med adsorption och eluering. I dagens läge genomför inte transfusionsmedicin i Karlskrona detta själva utan skickar proverna till Lund som genomför utredningen av G-antikroppar. Verifieringen genomfördes med hjälp av Lunds metodbeskrivningar för adsorption och eluering. Till verifieringen användes 7 patientprover som alla innehöll D och C-antikroppar, varav 5 kom från gravida kvinnor. Färska erytrocyter (< 72 h) användes för adsorption och eluering av antikropparna. Resultaten visade på att ett av proverna innehöll Gantikroppar i kombination med C-antikroppar och resterande sex prover innehöll D- och C-antikroppar. Resultaten blev som förväntat och metoden kunde godkännas för användning på transfusionsmedicin i Karlskrona.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Kuniechick, Natasha. "Produção do fator estimulador de colônias de granulócitos humano recombinante (rhG-CSF) em biorreator." Pontifícia Universidade Católica do Rio Grande do Sul, 2013. http://hdl.handle.net/10923/5520.

Повний текст джерела
Анотація:
Made available in DSpace on 2013-10-29T16:24:46Z (GMT). No. of bitstreams: 1 000451788-Texto+Completo-0.pdf: 1287455 bytes, checksum: d1990d71c198ca3db981a675db0e192b (MD5) Previous issue date: 2013
The granulocyte colony-stimulating factor (G-CSF) is a major hematopoietic cytokine involved in the immune defense against infectious agents, stimulating and regulating the proliferation, survival and differentiation of neutrophils precursor cells in the bone marrow. The G-CSF molecule has a 174 amino acids sequence, with a molecular weight of approximately 18. 8 kDa. As a strategy for neutropenia prevention, G-CSF (or filgrastim) has been successfully used in cancer patients whose treatment requires high doses of chemotherapy, in both adults and children. Moreover, this biopharmaceutical may be used to strengthen the immune system in patients with HIV, pneumonia, infections resulting from diabetes, leukemia and febrile neutropenia. Currently, filgrastim is not produced in Brazil, which obligates the government to import this medicine. Due to its wide clinical application, the large scale production of G-CSF is required to supply the demand of national market. In this work, a protocol to obtain this protein was developed using overexpression and cultivation in a bioreactor, solubilization and purification of recombinant G-CSF. The protein was expressed in Escherichia coli host cells C41(DE3) cultures grown in bioreactor using a fed-batch strategy. The expression of the recombinant protein was induced by IPTG. A linear ascending feeding strategy permitted high plasmid stability, low accumulation of acetate in the culture medium, a biomass of approximately 31 g/ L and high expression levels of the protein in the form of inclusion bodies which were solubilized using 2 M urea and alkaline pH. The recombinant protein was purified and yielded approximately 1. 22 mg of homogeneous recombinant protein per gram of wet cells, corresponding to a volumetric yield of 151. 5 mg of rhG-CSF per liter of culture medium. A mass spectrometry analysis was performed, confirming the identity of the recombinant protein. Our work shows a simple and effective strategy to obtain recombinant hG-CSF, stimulating and encouraging a future production of a national biosimilar.
O fator estimulador de colônias de granulócitos (G-CSF) é uma das principais citocinas hematopoiéticas envolvidas na defesa do sistema imune contra agentes infecciosos, estimulando e regulando a proliferação, sobrevivência e diferenciação das células precursoras de neutrófilos na medula óssea. É uma molécula que possui uma sequência de 174 aminoácidos, com peso molecular de aproximadamente 18,8 kDa. Como estratégia de prevenção da neutropenia, o G-CSF (ou filgrastima) é utilizado clinicamente com sucesso em pacientes com câncer, cujo tratamento requer altas doses de quimioterapia, tanto em adultos como em crianças. Além disso, o G-CSF pode ser utilizado para reforçar o sistema imunológico em pacientes com HIV, pneumonia, infecções decorrentes da diabetes, leucemia e neutropenia febril. Atualmente, a filgrastima não é produzida no Brasil, consequentemente, todo medicamento adquirido pelo governo é importado. Tendo em vista sua ampla aplicação clínica, a produção em larga escala do G-CSF se faz necessária para suprir a demanda do mercado nacional e diminuir os custos com importação desse biofármaco. Neste trabalho um protocolo para a produção desta proteína foi desenvolvido, utilizando técnicas de DNA recombinante por meio de experimentos de superexpressão e cultivo em biorreator, solubilização e purificação da G-CSF recombinante. A proteína foi expressa em células Escherichia coli C41(DE3) em cultivos de batelada alimentada em biorreactor, utilizando indução com IPTG e uma estratégia de alimentação linear ascendente, que nos permitiu obter um alto percentual de estabilidade plasmidial, baixo acúmulo de acetato no meio de cultivo, uma biomassa de aproximadamente 31 g/ L e elevados níveis de expressão da proteína em forma de corpos de inclusão, que foram solubilizados utilizando ureia 2 M e pH alcalino. A proteína recombinante foi purificada obtendo-se aproximadamente 1,22 mg de proteína recombinante homogênea por grama de células úmida, correspondendo a um rendimento volumétrico de 151,5 mg de rhG-CSF por litro de meio de cultura. Uma análise por espectrometria de massa também foi realizada, confirmando a identidade da proteína recombinante. Nosso trabalho mostra uma estratégia simples e eficaz para obter hG-CSF recombinante, contribuindo e estimulando a futura produção de um biossimilar nacional.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Gomes, Fernanda Resende. "Expressão do fator estimulador de colônia de granulócito humano recombinante (rhG-CSF) em Escherichia coli." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-13082010-163827/.

Повний текст джерела
Анотація:
O Fator estimulador de colônias de granulócitos humano recombinante (rhG-CSF) produzido em Escherichia coli é uma proteína não glicosilada com 175 aminoácidos, de grande importância clínica para o tratamento de neutropenias. O presente trabalho propõe a construção de dois sistemas de expressão em E. coli, um sistema para obtenção do rhG-CSF no citoplasma e outro para secreção da proteína recombinante no meio de cultura utilizando a sequência sinal da L-asparaginase II. Os dois sistemas de expressão foram testados e comparados. A partir desses dados, passou-se para as etapas de obtenção do rhG-CSF com o sistema de expressão sem a sequência sinal. As etapas de renaturação e purificação foram eficientes obtendo-se uma proteína com adequado grau de pureza, integridade estrutural e atividade biológica. Essa proteína também foi utilizada com sucesso para a produção de anticorpos policlonais em camundongos. Com os resultados obtidos, a proteína rhG-CSF mostrou-se viável para estudos posteriores em bioreatores e produção em escala-piloto.
The recombinant human granulocyte colony stimulating factor (rhG-CSF) is a non-glycosylated protein with 175 amino acids. This factor plays an important role in hematopoietic cell proliferation and has been widely used for treating neutropenia. The purpose of this work is to construct two expression systems in E. coli; a system for obtaining rhG-CSF in the cytoplasm and the other for secretion of recombinant protein in the culture medium using the signal sequence of L-asparaginase II. The two expression systems were tested and compared. From these data, the next steps for obtaining the rhG-CSF were done with the expression system without the signal sequence. The refolding and purification steps were efficient, resulting in a protein with adequate purity, structural integrity and biological activity. This protein has also been successfully used for the production of polyclonal antibodies in mice. With these results, the protein rhG-CSF was feasible for further studies in bioreactors and pilot scale production.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Carmo, Fillipe Luiz Rosa do. "Clonagem, expressão e caracterização do fator estimulador de colônia de granulócito humano recombinante (rhG-CSF) em Escherichia coli." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/60/60135/tde-17042015-112052/.

Повний текст джерела
Анотація:
O sistema de expressão em Escherichia coli foi o primeiro a ser utilizado para produzir produtos farmacêuticos recombinantes e tem muitas vantagens quando comparado com sistemas eucarióticos, como o fácil cultivo, baixo custo e alto potencial de produção. O fator estimulador de colônias de granulócito (G-CSF) atua principalmente promovendo a maturação dos neutrófilos e estimulando sua atividade fagocítica e quimiotática, além de estar envolvido com o processo de segmentação nuclear dessas células. O fator estimulador de colônias de granulócitos humano recombinante (rhG-CSF) tem sido produzido por engenharia genética em Escherichia coli, e é usado no tratamento de diversas patologias, sobretudo em neutropenias provocadas pela quimioterapia usada no tratamento de tumores, pela radioterapia e pelo uso de drogas que suprimem a produção de células mieloides. Desse modo, o presente estudo teve como objetivo a expressão da proteína rhGCSF em bactérias Escherichia coli. A clonagem do gene rhG-CSF no vetor de expressão pET-28a(+) foi realizada nos sítios de restrição das enzimas EcoRI e XhoI, e a expressão da proteína recombinante em cepas de bactéria Escherichia coli BL21DE3 foi obtida com sucesso. A proteína rhG-CSF, fundida à cauda de seis histidinas, foi purificada com êxito e identificada pelas técnicas de Western Blotting e por espectrometria de massas. São necessários estudos para avaliar a integridade estrutural e atividade biológica da proteína produzida, que se confirmada, possibilita que esta seja produzida em escala piloto.
The expression system in Escherichia coli was the first to be used to produce recombinant pharmaceuticals and has many advantages compared to eukaryotic systems, such as easy cultivation and high production potential at low costs. The granulocyte colony (G-CSF) stimulating factor acts primarily by promoting the maturation of neutrophils and stimulating their phagocytic and chemotactic activity. G-CSF is also involved with the process of neutrophils nuclear segmentation. The recombinant human granulocyte colonies stimulating factor (rhG-CSF) has been produced by genetic engineering in Escherichia coli, and it is used to treat of several conditions, especially neutropenia caused by chemotherapy used in the treatment of tumors, by radiotherapy and by the use of drugs that suppress the production of myeloid cells. The present study aimed the expression of rhG-CSF protein in Escherichia coli bacteria. The cloning of rhG-CSF gene in the expression vector pET- 28a (+) was carried out on the restriction sites of the EcoRI and XhoI enzymes. Expression of the recombinant protein in Escherichia coli BL21DE3 was successfully achieved. The rhG-CSF protein, fused with a six histidine tag, was obtained and successfully purified and identified by the Western Blotting and by mass spectrometry techniques. Studies are needed to assess the structural integrity and biological activity of the protein produced, which, if confirmed, enables the production on a pilot scale.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Kuniechick, Natasha. "Produ??o do fator estimulador de col?nias de granul?citos humano recombinante (rhG-CSF) em biorreator." Pontif?cia Universidade Cat?lica do Rio Grande do Sul, 2013. http://tede2.pucrs.br/tede2/handle/tede/5478.

Повний текст джерела
Анотація:
Made available in DSpace on 2015-04-14T14:51:30Z (GMT). No. of bitstreams: 1 451788.pdf: 1287455 bytes, checksum: d1990d71c198ca3db981a675db0e192b (MD5) Previous issue date: 2013-03-27
The granulocyte colony-stimulating factor (G-CSF) is a major hematopoietic cytokine involved in the immune defense against infectious agents, stimulating and regulating the proliferation, survival and differentiation of neutrophils precursor cells in the bone marrow. The G-CSF molecule has a 174 amino acids sequence, with a molecular weight of approximately 18.8 kDa. As a strategy for neutropenia prevention, G-CSF (or filgrastim) has been successfully used in cancer patients whose treatment requires high doses of chemotherapy, in both adults and children. Moreover, this biopharmaceutical may be used to strengthen the immune system in patients with HIV, pneumonia, infections resulting from diabetes, leukemia and febrile neutropenia. Currently, filgrastim is not produced in Brazil, which obligates the government to import this medicine. Due to its wide clinical application, the large scale production of G-CSF is required to supply the demand of national market. In this work, a protocol to obtain this protein was developed using overexpression and cultivation in a bioreactor, solubilization and purification of recombinant G-CSF. The protein was expressed in Escherichia coli host cells C41(DE3) cultures grown in bioreactor using a fed-batch strategy. The expression of the recombinant protein was induced by IPTG. A linear ascending feeding strategy permitted high plasmid stability, low accumulation of acetate in the culture medium, a biomass of approximately 31 g/ L and high expression levels of the protein in the form of inclusion bodies which were solubilized using 2 M urea and alkaline pH. The recombinant protein was purified and yielded approximately 1.22 mg of homogeneous recombinant protein per gram of wet cells, corresponding to a volumetric yield of 151.5 mg of rhG-CSF per liter of culture medium. A mass spectrometry analysis was performed, confirming the identity of the recombinant protein. Our work shows a simple and effective strategy to obtain recombinant hG-CSF, stimulating and encouraging a future production of a national biosimilar.
O fator estimulador de col?nias de granul?citos (G-CSF) ? uma das principais citocinas hematopoi?ticas envolvidas na defesa do sistema imune contra agentes infecciosos, estimulando e regulando a prolifera??o, sobreviv?ncia e diferencia??o das c?lulas precursoras de neutr?filos na medula ?ssea. ? uma mol?cula que possui uma sequ?ncia de 174 amino?cidos, com peso molecular de aproximadamente 18,8 kDa. Como estrat?gia de preven??o da neutropenia, o G-CSF (ou filgrastima) ? utilizado clinicamente com sucesso em pacientes com c?ncer, cujo tratamento requer altas doses de quimioterapia, tanto em adultos como em crian?as. Al?m disso, o G-CSF pode ser utilizado para refor?ar o sistema imunol?gico em pacientes com HIV, pneumonia, infec??es decorrentes da diabetes, leucemia e neutropenia febril. Atualmente, a filgrastima n?o ? produzida no Brasil, consequentemente, todo medicamento adquirido pelo governo ? importado. Tendo em vista sua ampla aplica??o cl?nica, a produ??o em larga escala do G-CSF se faz necess?ria para suprir a demanda do mercado nacional e diminuir os custos com importa??o desse biof?rmaco. Neste trabalho um protocolo para a produ??o desta prote?na foi desenvolvido, utilizando t?cnicas de DNA recombinante por meio de experimentos de superexpress?o e cultivo em biorreator, solubiliza??o e purifica??o da G-CSF recombinante. A prote?na foi expressa em c?lulas Escherichia coli C41(DE3) em cultivos de batelada alimentada em biorreactor, utilizando indu??o com IPTG e uma estrat?gia de alimenta??o linear ascendente, que nos permitiu obter um alto percentual de estabilidade plasmidial, baixo ac?mulo de acetato no meio de cultivo, uma biomassa de aproximadamente 31 g/ L e elevados n?veis de express?o da prote?na em forma de corpos de inclus?o, que foram solubilizados utilizando ureia 2 M e pH alcalino. A prote?na recombinante foi purificada obtendo-se aproximadamente 1,22 mg de prote?na recombinante homog?nea por grama de c?lulas ?mida, correspondendo a um rendimento volum?trico de 151,5 mg de rhG-CSF por litro de meio de cultura. Uma an?lise por espectrometria de massa tamb?m foi realizada, confirmando a identidade da prote?na recombinante. Nosso trabalho mostra uma estrat?gia simples e eficaz para obter hG-CSF recombinante, contribuindo e estimulando a futura produ??o de um biossimilar nacional.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Wiik, H. (Heikki). "Inflammatory response following abdominal surgery and its modulation by recombinant human granulocyte colony-stimulating factor (rhG-CSF, filgrastim)." Doctoral thesis, University of Oulu, 2002. http://urn.fi/urn:isbn:9514268474.

Повний текст джерела
Анотація:
Abstract The effects of perioperative filgrastim (rhG-CSF) and surgery per se on the postoperative acute phase reaction were studied by assessing leukocyte functions, cytokine levels and tenascin-C (Tn-C) and procollagen propeptide (PINP, PIIINP) concentrations in different body fluid compartments in patients undergoing gastrointestinal surgery. Thirty consecutive patients were randomized to receive either filgrastim or placebo for five days, starting 12 hours before colorectal surgery. Filgrastim treatment led to marked neutrophilia with decreased neutrophil migration in peripheral blood but not in peritoneal fluid 48 hours postoperatively. Neutrophil phagocytosis and bacterial killing did not differ between the groups. Filgrastim caused increased postoperative expression of neutrophil CD11b/CD18 in blood but not in peritoneal fluid or wound fluid. CD11b/CD18 expression was higher in both wound fluid and peritoneal fluid than in blood in the placebo group. The expression of neutrophil CD62L was higher in blood than in peritoneal fluid or wound fluid in both groups. The serum concentration of interleukin (IL)-8 was lower in the filgrastim group 5 hours postoperatively. The concentrations of IL-1β, IL-6, transforming growth factor (TGF)-β and IL-10 did not differ between the groups. The cytokine levels were markedly higher locally in the wound and in the peritoneal cavity compared to circulating blood. No adverse events attributable to filgrastim were seen. Leukocyte counts, neutrophil and monocyte functions and the levels of IL-6, IL-8 and granulocyte colony-stimulating factor (G-CSF) were measured from 18 patients before and after colorectal surgery. Surgery caused an increase in neutrophil and monocyte counts along with lymphocytopenia. Neutrophil phagocytosis was decreased 4 and 24 hours postoperatively, but normalized after that. A distinct systemic cytokine response was seen postoperatively. In a study with 24 patients, Tn-C concentration increased in wound fluid during the first postoperative week after abdominal surgery. The Tn-C level was markedly higher in wound fluid than in serum.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Granström, Pontus, Lisa Larsson, and Oscar Lönnerheden. "”Handboll är ju en så jävla komplex sport” : Kompetenskrav i elithandboll, en jämförelse mellan elitlagstränare och RHG-instruktörer." Thesis, Linnéuniversitetet, Institutionen för idrottsvetenskap (ID), 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-45551.

Повний текст джерела
Анотація:
I Sverige ger Riksidrottsgymnasier (RIG) elever chansen att kombinera sina studier med idrott. Målen med RIG innefattar att eleverna som examineras ska ges goda förutsättningar att lyckas nå internationell elitnivå som senior. Statistik över hur RIG-studenter uppfyller dessa mål saknas dock. Syftet med uppsatsen är att analysera vad som ligger i kompetensbegreppet elithandbollspelare ur en elitlagstränares synvinkel samt att jämföra detta med hur instruktörerna vid Rikshandbollsgymnasiet (RHG) uppfattar samma begrepp. Det är också vår ambition att redogöra för elithandbollstränares uppfattning om skillnader mellan examinerade elever från RIG-handboll och spelare som gått Nationell idrottsutbildning (NIU) eller gymnasium utan handbollsinriktning. Genom en kvalitativ studie har vi med semistrukturerade intervjuer och en fokusgrupp samlat in empiri från ett målinriktat urval. I analysen ställs empirin mot tidigare forskning och de teorier vi redogör för. Studiens resultat visar att synen på kompetens som krävs för en elithandbollspelare till stor del är likvärdig mellan elitlagstränare och instruktörer vid RHG. Generellt har elitlagstränare inom den svenska handbollen bättre kunskap om NIU och är osäkra om skillnaden mellan NIU och RIG. Även kunskapen om spelare som går eller har gått RHG är låg hos elittränarna. Den största skillnad som elittränarna ser mellan RHG-studenter och andra spelare är att RHG spelare upplevs som proffsigare och mer teoretiskt kunniga.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Azevedo, Wellington Morais de. "Transplante alogenico de celulas-tronco perifericas mobilizadas por rhG-CSF, não manipuladas in vitro, para tratamento de neoplasias hematologicas." [s.n.], 1995. http://repositorio.unicamp.br/jspui/handle/REPOSIP/308632.

Повний текст джерела
Анотація:
Orientador: Carmino Antonio de Souza
Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-07-20T17:36:43Z (GMT). No. of bitstreams: 1 Azevedo_WellingtonMoraisde_D.pdf: 3412808 bytes, checksum: 37fe74ea6f2a3b91910127765c8e266e (MD5) Previous issue date: 1995
Resumo: Transplantes autoplásticos de células-tronco periféricas (CTP) já vêm sendo realizados há algum tempo, tendo mostrado algumas vantagens em relação aos transplantes do mesmo tipo que utilizam medula óssea. Dentre estas vantagens, destaca-se a capacidade das CTP de produzir uma "pega" mais rápida do enxerto, encurtando o período de aplasia de medula óssea que se segue ao condicionamento do paciente. A coleta de CTP por aférese oferece maior conforto ao doador, que não precisa ser submetido à anestesia geral e às numerosas punções da crista ilíaca necessárias à obtenção do número de células suficientes para o transplante. Apesar das evidentes vantagens observadas no cenário autoplástico, a aplicação da mesma técnica aos transplantes alogênicos só se iniciou no começo dos anos 90. Este retardo se deveu ao temor de que os enxertos de CTP alogênicas, mais ricos em células T imunocompetentes, pudessem acarretar aumentos na incidência e gravidade da doença do enxerto-contra-o-hospedeiro (DECH). Outro empecilho à realização desses transplantes é a ecessidade de mobilização das CTP para a circulação sangüínea, que se fez possível nos transplantes autoplásticos, inicialmente, pelo uso de quimioterápicos citotóxicos; tal prática seria eticamente condenável em doadores sadios e, só mais recentemente, os fatores de crescimento hematopoiético humanos, obtidos por tecnologia de recombinação gênica (rhGCSF), ofereceram uma alternativa mais segura para conseguir essa mobilização. Neste estudo, não controlado analisamos os resultados de dezessete transplantes alogênios de CTP, comparando-os com aqueles obtidos em um grupo-controle que recebeu, contemporaneamente, transplantes alogênicos convencionais de medula óssea. O objetivo foi o de se estudar, comparativamente, o perfil de "pega" dos enxertos de CTP, assim como a morbidade associada ao procedimento. Para tanto, foram comparados vários parâmetros entre os dois grupos, que incluíram: tempo de "pega" do enxerto, tempo de permanência no hospital após o transplante, necessidade de transfusões, número de dias em uso de antimicrobianos ou nutrição parenteral, níveis séricos máximos de creatinina e bilirrubina, incidência e gravidade de DECH aguda, entre outros. Procuramos avaliar ainda os eventuais efeitos colaterais a curto prazo do rhG-CSF nos doadores. Os resultados mostraram que a incidência e gravidade da DECH aguda foram comparáveis entre os dois grupos, assim como a morbidade geral relacionada ao transplante. De fato, os transplantes com CTP apresentaram "pega" mais rápida e permitiram alta hospitalar mais precoce. A mobilização de CTP pelo uso de rhG-CSF e sua obtenção por sessões únicas de aférese mostraram-se, no período estudado, livres de efeitos colaterais ou complicações clínicas sérias para os doadores. O número de células foi suficiente para garantir a "pega" e estabilidade do enxerto em todos os pacientes, não se observando rejeições ou "falhas de pega". Aparentemente, as vantagens oferecidas pelas CTP em transplantes autoplástiéos também se aplicam aos transplantes alogênicos. Os resultados sugerem ser a técnica viável, porém devem ser interpretados com cautela devido às limitações metodológicas do estudo, que incluem o curto tempo de seguimento dos pacientes e a realização de análise de dados de grupos de pacientes distribuídos sem "randomização"
Abstract: Autologous blood stem celI (BSC) transplantation is already a welI established medical procedure, which has shown some advantages over the use of bone marrow for the same purpose. A faster engraftment rate is observed in these transplants, consequently shortening the period of marrow aplasia that folIows the conditioning phase. Besides, BSC colIection by apheresis offers more cornfort to the donors, avoiding the need for general anesthesia and marrow aspiration in order to obtain sufficient numbers of stem celIs for engraftment. Despite alI these advantages, the use of allogeneic BSC for transplantation did not start until the beginning of the Nineties. The application of the technique had always been hampered by the fear. that BSC grafts, which contain a larger amount of immunocompetent T -celIs, could result in intolerable increases of graft-versus-host disease (GVHD) incidence and severity. ColIection ofBSC by apheresis requires that these celIs first be mobilized to the circulation, a task acomplished initially by the use of antinoeplastic cytotoxic drugs. The administration of such agents to healthy donors would be a clearly unnacceptable practice, and, only Tecently, recombinant human hematopoietic growth factors (rhG-CSF) have offered a reasonable alternative for this purpose. In thi~ study, we retrospectively analyze the results of seventeen allogeneic BSC transplants, comparing them to those obtained in a control group of patients who received conventional allogeneic marrow transplants contemporarily fashion. The objective was to study the engraftment profile of the BSC grafts, as welI as the general transplant-associated morbidity. For this purpose, several parameters were assessed and compared between the two groups, including: time to engraftment, transfusion needs, number of days under antimicrobial treatment and parenteral nutrition, maximal serum levels of creatinine and bilirubin, incidence and severity of acute GVHD, among others. We also analyzed the eventual short-term deleterious effects of rhG-CSF upon donors. The results have pointed to a comparable incidence and severity of acute GVHD in the two populations, as well as similar transplant-associated morbidity profiles. Indeed, BSC grafts produced significantly faster engraftment and shorter hospital stays. Donor stem cell mobilization by rhG-CSF and their collection by single apheresis sessions have been devoid of significant side-effects or clinical complications in the study period. The numbers of cells collected have always proven sufficient to promote good engraftment, with no documentated of rejection or any other kind of graft failure. It seems apparent that the advantages offered by autologous BSC transplants can be shared by their allogeneic counterparts. The results suggest that allogeneic BSC transplantation is a feasible procedure, but one must not forget that this was not a randomized, prospective study, and that our follow-up time was not long enough to permit safe conclusions about the issue. More studies are necessary until we can replace alogeneic BSC transplantation for conventional bone marrow transplants
Doutorado
Clinica Medica
Doutor em Clínica Médica
Стилі APA, Harvard, Vancouver, ISO та ін.
9

RONZINO, ANDREA. "Unpacking Robin Hood gardens: the troubled history of a British public housing project (1952) 1963/1972 (2018)." Doctoral thesis, Politecnico di Torino, 2021. http://hdl.handle.net/11583/2914548.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Kazi, Samreen H. "Minimum tile-derived microsatellite markers improve the physical map of the soybean genome and the Flyer and Hartwig genetic map at Rhg, Rfs and yield loci /." Available to subscribers only, 2005. http://proquest.umi.com/pqdweb?did=1075682461&sid=1&Fmt=2&clientId=1509&RQT=309&VName=PQD.

Повний текст джерела
Анотація:
Thesis (M.S.)--Southern Illinois University Carbondale, 2005.
"Department of Molecular Biology, Microbiology and Biochemisty." Includes bibliographical references (leaves 154-176). Also available online.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "RHG"

1

École nationale supérieure d'architecture de Paris-Belleville, ed. RHG/ENSAPB: [Direction de l'ouvrage, Ginette Baty-Tornikian]. Paris: Éditions Recherches, 2006.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Lhuiṅʻ, Kraṅʻ. Budha bhu rā ̋ rhaṅʻ sakʻ toʻ thaṅʻ rhā ̋rhi cañʻ kāla n* thaṅʻ rhā ̋ so tanʻ khui ̋ rhaṅʻ myā ̋. (Ranʻ kunʻ): Cā ʼupʻ myā ̋puṃ nhipʻ thut ve re ̋ koʻmatī, ʼA myui ̋ sā ̋ lūʹ cvamʻ ̋ʼa ̋ʼa raṅʻ ̋ʼa mracʻ phvaṃʹ phrui ̋ mhu ṭhāna, Paññʻa re ̋ vanʻ krī ̋ ṭhāna, 2003.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Corporation, Gateway Learning, ed. Rag. [Foster City, Calif.]: Gateway Learning Corporation, 1998.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Barker, Nicholas. Rig. London: W.H.Allen, 1990.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Julie, Carr. Rag. Richmond, California: Omnidawn Publishing, 2014.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Fishār-i reg: Fishaar-e-reg. Ḥaidarābād: al-Anṣār Pablīkeshanz, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Chve, Sanʻʺ. Phve phve rhā rhā samuiṅʻʺ cā. Ranʻ kunʻ: Kaṃʹ koʻ vatʻ raññʻ Cā pe, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kyoʻ, ʼOṅʻ. Tacche ta kayʻ rhi ma rhi. Ranʻ kunʻ: ʼA suiṅʻʺ ʼA vuiṅʻʺ Cā pe, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Rtsom rig gśib bsdur rig lam. Pe-cin: Mi rigs dpe skrun khaṅ, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Gso rig dang gnam rig skor rtsis. [Lha-sa]: Bod ljongs mi dmangs dpe skrun khang, 2014.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "RHG"

1

Drize, N. J., J. L. Chertkov, and A. R. Zander. "Combination of rhSCF + rhG-SCF, But Not rhG-CSF Alone Potentiate the Mobilization of Hematopoietic Stem Cells with Increased Repopulating Ability into Peripheral Blood of Mice." In Acute Leukemias V, 391–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-78907-6_66.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Gross-Weege, W., M. Weiss, M. Wenning, M. Schneider, C. Ohmann, and H. Becker. "Phase II-Studie zur Prophylaxe und Therapie der Sepsis bei chirurgischen, intensiv-therapiepflichtigen Patienten mit rhG-CSF." In Chirurgisches Forum ’94, 423–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78905-2_84.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Andreeff, M., A. Tafuri, and S. Hegewisch-Becker. "Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside." In Acute Leukemias II, 747–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_137.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Bauhofer, A., M. Huttel, K. P. Reimund, I. Celik, B. Greger, and W. Lorenz. "Wirksame Prophylaxe mit rhG-CSF bei abdomineller Sepsis: Verbesserung antimikrobieller Funktionen von Granulocyten als neuer Mechanismus in vivo." In Chirurgisches Forum ’97 für experimentelle und klinische Forschung, 593–96. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60717-2_119.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Moore, M. A. S., K. Welte, J. Gabrilove, and L. M. Souza. "Biological Activities of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) and Tumor Necrosis Factor: In Vivo and In Vitro Analysis." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 210–20. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72624-8_45.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kröger, N., H. Renges, W. Krüger, K. Gutensohn, C. Löliger, I. Carrero, B. Cortez, and A. R. Zander. "A Randomized Comparison of Once Versus Twice Daily rhG-CSF (Filgrastim) for Stem Cell Mobilisation in Healthy Donors for Allogeneic Transplantation." In Transplantation in Hematology and Oncology II, 138–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55774-3_17.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Gass, Saul I., and Carl M. Harris. "RHS." In Encyclopedia of Operations Research and Management Science, 720. New York, NY: Springer US, 2001. http://dx.doi.org/10.1007/1-4020-0611-x_894.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Gooch, Jan W. "Rhe." In Encyclopedic Dictionary of Polymers, 631. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_10021.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Zahid, Sarwar, Kari Branham, Dana Schlegel, Mark E. Pennesi, Michel Michaelides, John Heckenlively, and Thiran Jayasundera. "RHO." In Retinal Dystrophy Gene Atlas, 215–18. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-10867-4_67.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Shoff, William H., Catherine T. Shoff, Suzanne M. Shepherd, Jonathan L. Burstein, Calvin A. Brown, Ashita J. Tolwani, Bala Venkatesh, et al. "RBG." In Encyclopedia of Intensive Care Medicine, 1955. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_2134.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "RHG"

1

Huot, N., G. Pauliat, J. M. C. Jonathan, G. Roosen, R. Scharfschwerdt, O. F. Schirmer, and D. Rytz. "Four fold improvement of the photorefractive time constant of BaTiO3:Rh by oxidation." In The European Conference on Lasers and Electro-Optics. Washington, D.C.: Optica Publishing Group, 1998. http://dx.doi.org/10.1364/cleo_europe.1998.cfe2.

Повний текст джерела
Анотація:
Our spectroscopic studies have shown without ambiguity that the three charge states Rh3+, Rh4+, Rh5+ are responsible at 1.06 µm for the optical absorption and charge redistribution through hole photoconductivity in rhodium doped barium titanate [1]. From this three charge state model, we solved the charge transfer equations and used the obtained results to characterize as grown samples at 1.06 µm through induced absorption and two-wave mixing experiments [2]. A major feature is that the photoexcitation cross section from Rh5+ to the valence band is about 75 times larger than the one from Rh4+. These previous results suggest that the photorefractive rise time could be decreased by lowering the Fermi level by oxidation. This removes the positive charges of oxygen vacancies which compensate the negative charges of acceptors being present in the crystal. Compensation is then achieved by the positive charges of holes captured at Rh3+ (forming Rh4+) or at Rh4+ (forming Rh5+).
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Freudenreich, Klaus. "Rho-rho production in two-photon collisions." In International Europhysics Conference on High Energy Physics. Trieste, Italy: Sissa Medialab, 2007. http://dx.doi.org/10.22323/1.021.0112.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Celepcikay, Oner Ulvi, and Christoph F. Eick. "REG^2." In the 17th ACM SIGSPATIAL International Conference. New York, New York, USA: ACM Press, 2009. http://dx.doi.org/10.1145/1653771.1653816.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Bai, Bo (Bob), Wei Chen, Khaled Ben Letaief, and Zhigang Cao. "RBG matching." In the 6th International Wireless Communications and Mobile Computing Conference. New York, New York, USA: ACM Press, 2010. http://dx.doi.org/10.1145/1815396.1815540.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Marquis Bolduc, Mathieu, and Hau Nghiep Phan. "Rig Inversion by Training a Differentiable Rig Function." In SA '22: SIGGRAPH Asia 2022. New York, NY, USA: ACM, 2022. http://dx.doi.org/10.1145/3550340.3564218.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Vishwakarm, K., M. Chaturvedi, O. Ojo, and P. Wanjara. "Linear Friction Welding of Allvac® 718Plus® Superalloy." In Superalloys. John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.7449/2010/superalloys_2010_413_426.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Andersson, J., G. Sjöberg, and M. Chaturvedi. "Hot Ductility Study of HAYNES® 282® Superalloy." In Superalloys. John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.7449/2010/superalloys_2010_539_554.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Biajone, Jefferson, Vitor Emanuel Queiroz Ferreira, Andressa Silvério Terra França, Maylon Pires Macedo, and Guilherme Rosa de Moraes. "Fatec RPG: Jogo interativo via RPG Maker VX Ace." In 13th CONTECSI International Conference on Information Systems and Technology Management. TECSI, 2016. http://dx.doi.org/10.5748/9788599693124-13contecsi/pst-1018.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

"Reg-1: Registration." In 2017 9th IEEE-GCC Conference and Exhibition (GCCCE). IEEE, 2017. http://dx.doi.org/10.1109/ieeegcc.2017.8448042.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Costa, Alexandre Monte Alto, Ricardo Tolosa, Sidnei Kameoka, and Luis Fernando Caldo. "Rig Tests Optimization." In SAE Brasil 2003 Congress and Exhibit. 400 Commonwealth Drive, Warrendale, PA, United States: SAE International, 2003. http://dx.doi.org/10.4271/2003-01-3693.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "RHG"

1

Falk, A. Comment on Extracting alpha from B to rho rho. Office of Scientific and Technical Information (OSTI), October 2003. http://dx.doi.org/10.2172/826521.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Bevan, A. Measurements of sin2 alpha phi_2 from B to pi pi, rho pi and rho rho Modes. Office of Scientific and Technical Information (OSTI), November 2004. http://dx.doi.org/10.2172/839802.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Meyer, William R. Rocket Propelled Grenade (RPG), RPG-7VM, MIL-STD-1660 Tests. Fort Belvoir, VA: Defense Technical Information Center, August 1995. http://dx.doi.org/10.21236/ada391649.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Boone, S. G. TRU VU rig instrumentation. Office of Scientific and Technical Information (OSTI), February 1993. http://dx.doi.org/10.2172/6745935.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Ramey, Garey, and Valerie Ramey. The Rug Rat Race. Cambridge, MA: National Bureau of Economic Research, August 2009. http://dx.doi.org/10.3386/w15284.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Schock, Alfred. Mars Rover RTG Study. Office of Scientific and Technical Information (OSTI), October 1989. http://dx.doi.org/10.2172/1033348.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Schock, Alfred. Mars Rover RTG Study. Office of Scientific and Technical Information (OSTI), November 1989. http://dx.doi.org/10.2172/1033388.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Schock, Alfred. Mars Rover RTG Study. Office of Scientific and Technical Information (OSTI), August 1989. http://dx.doi.org/10.2172/1033423.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kelly, C. E., and P. M. Klee. Cassini RTG acceptance test results and RTG performance on Galileo and Ulysses. Office of Scientific and Technical Information (OSTI), June 1997. http://dx.doi.org/10.2172/481894.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Aubert, B. Observation of e+e- Annihilations into the C=+1 Hadronic Final States \rho^0\rho^0 and \phi\rho^0. Office of Scientific and Technical Information (OSTI), June 2006. http://dx.doi.org/10.2172/885278.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "RHG" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії